Back to Search
WILLIAM FIGG, PHARM.D.
PHARM.D.
Oncology Pharmacist
NPI: 1780565010Individual
Specialties, Licenses & Credentials
Oncology PharmacistPrimary
Pharmacist — Oncology
Code: 1835X0200X
0202011192(VA)
Research & Publications (20)
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
PMID 19167733·J Urol·2009
2-rct
Pharm. D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy research.
PMID 18576897·Pharmacotherapy·2008
8-other
The Pharm.D. investigator in clinical pharmacology: supply and demand.
PMID 19238658·Clin Pharmacol Ther·2008
8-other
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
PMID 17437439·BJU Int·2007
3-trial
Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokinetics.
PMID 16880730·Cancer Biol Ther·2006
8-other
Scientific collaboration results in higher citation rates of published articles.
PMID 16716129·Pharmacotherapy·2006
8-other
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer.
PMID 16413236·Clin Pharmacol Ther·2006
8-other
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
PMID 15711271·J Urol·2005
3-trial
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.
PMID 15592675·World J Urol·2004
8-other
Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.
PMID 12099578·Invest New Drugs·2002
6-review
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
PMID 11685731·Semin Oncol·2001
3-trial
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
PMID 11448901·Clin Cancer Res·2001
3-trial
Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study.
PMID 19431146·Int J Cancer·2009
8-other
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation.
PMID 19433787·Proc Natl Acad Sci U S A·2009
7-preclinical
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
PMID 19451403·J Clin Pharmacol·2009
3-trial
VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
PMID 19483467·Cancer Biol Ther·2009
7-preclinical
Urine analysis and protein networking identify met as a marker of metastatic prostate cancer.
PMID 19549766·Clin Cancer Res·2009
8-other
Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.
PMID 19591692·J Exp Clin Cancer Res·2009
7-preclinical
Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism.
PMID 19589782·J Biol Chem·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 9000 ROCKVILLE PIKE RM 5A03
BETHESDA, MD 20892 - Phone
- (240) 338-6898
Quick Facts
- NPI
- 1780565010
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile